Should I buy McKesson Corporation (MCK) stock or is it too late?

McKesson Corporation · Health Care · price $891
Logo McKesson CorporationSee the full McKesson Corporation (MCK) profile
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Citigroup66% of its targets hit on this sector (508 calls tested). It aims for $1,000 (+12 %), call made on July 25, 2026, maturing on July 25, 2027 (34 d ago).

The 5 reliable analysts $1,000+12 %
The 4 other firms $1,000+12 %
How to read it: the 5 reliable firms are not filtered by optimism — 5 aim above the price, 0 below, hence their $1,000 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on McKesson Corporation

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Citigroup90 %+32.0 %10$1,000 +12%
UBS100 %+31.3 %11$1,080 +21%
Morgan Stanley97 %+29.7 %29$916 +3%
Baird92 %+24.6 %12$927 +4%
Evercore ISI Group86 %+21.9 %7$1,000 +12%
Deutsche Bank70 %+17.8 %10$856 -4%
JP Morgan60 %+15.8 %10$1,015 +14%
Barclays54 %+14.0 %13$1,000 +12%
In short — Should you invest in McKesson Corporation? Is it too late, still worth it? Analysts are overwhelmingly positive (80% buy, median target $1,000, i.e. +12%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • 80% of analysts rate it a buy (Buy consensus, 10 ratings) — a sign of market conviction.
  • Median price target $1,000, i.e. +12% from the current price ($891).

⚠️ Reasons to hesitate

  • Even the most reliable firm on MCK, Leerink Partners (100% hit rate, 3 scored calls), only targets $850 (call made on September 24, 2025, maturing on September 24, 2026) (-5%) in its most recent call. The stock may already have run past its target.
  • The consensus is not unanimous: of 10 ratings, 2 are neutral.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • Negligible dividend (0.4% yield): your return depends mostly on price appreciation.

The analyst consensus on MCK

Median target $1,000 (+12%) · 10 ratings · Buy consensus

Strong Buy00%
Buy880%
Hold220%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in McKesson Corporation now?

We won't decide for you. The facts: 80% of analysts rate it a buy, median target $1,000 (+12%), and Leerink Partners (most reliable on MCK, 100%) targets $850. Weigh that against valuation (P/E ~24). This is not personalized advice.

Is it too late to invest in McKesson Corporation?

Not according to analysts: the median target ($1,000) is still +12% above the current price ($891) (most reliable on MCK: Leerink Partners, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is McKesson Corporation still worth investing in?

It depends on the gap between the price ($891) and its estimated value: analysts target $1,000 on median (+12%), with 80% buys (most reliable on MCK: Leerink Partners, 100%). Cross-check with their real reliability on MCK and the cautions above. Information, not advice.

What's the main risk in buying MCK?

Even the most reliable firm on MCK, Leerink Partners (100% hit rate, 3 scored calls), only targets $850 (call made on September 24, 2025, maturing on September 24, 2026) (-5%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full McKesson Corporation profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)